Brought to you by 
Intradigm helps to improve delivery of Acuity eye candidate
19 Sep 2005
Executive Summary
Intradigm Corp. and Acuity Pharmaceuticals (both focus on RNAi interference) will collaborate to develop topical formulations and perhaps additional delivery modes for Acuity's lead compound, Cand5. The first RNAi candidate ever to enter clinical studies, it is finishing Phase I now.
Deal Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intradigm helps to improve delivery of Acuity eye candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice